Incyte : INCY

All Incyte Articles

137 Articles

Lee Jackson | Apr 15, 2017 at 9:20 AM EDT

Analysts See 10 Companies Beating Expectations This Earnings Season

With earnings starting to really snowball next week, and a market that seems to be teetering somewhat due to high…

Lee Jackson | Apr 10, 2017 at 9:50 AM EDT

Jefferies Thinks 3 Red-Hot Biotech Stocks Can Beat Q1 Estimates

A massive new Jefferies research report reminds investors that as a rule the first quarter is traditionally slower for biotechnology…

Paul Ausick | Apr 1, 2017 at 9:15 AM EDT

The 5 Best Performing S&P 500 Stocks for Q1

The first quarter's top-performing stocks in the S&P 500 index included two pharmaceutical firms, an electricity generator, a video game…

Jon C. Ogg | Mar 28, 2017 at 12:10 PM EDT

Top-Performing S&P 500 Stocks Already Showing Gains of 30% to 50% in 2017

24/7 Wall St. tracked the best performing members of the S&P 500 Index on a year-to-date basis. It turns out…

Chris Lange | Mar 13, 2017 at 10:35 AM EDT

What a Combined Gilead and Incyte Would Look Like

Gilead Sciences has long been in need of a catalyst to move its business, and a lot of investors and…

Chris Lange | Feb 13, 2017 at 9:45 AM EST

Top 5 Earnings to Look For on Tuesday

24/7 Wall St. has put together a preview of Express Scripts, T-Mobile and some of the other most anticipated quarterly…

Chris Lange | Jan 30, 2017 at 10:50 AM EST

Why This Collaboration Is So Important for Calithera

Shares of Calithera Biosciences saw a solid gain early on Monday after the company reported a global collaboration and licensing…

Chris Lange | Jan 23, 2017 at 12:35 PM EST

Why Credit Suisse Sees Incyte Rising Over 15%

Credit Suisse sees future earnings growth from Incyte’s pipeline, with epacadostat’s potential as a best-in-class immunotherapy combination agent making the…

Jon C. Ogg | Jan 23, 2017 at 9:15 AM EST

Top Analyst Upgrades and Downgrades: Ally, IBM, MetLife, Qualcomm, Verizon, Williams, Incyte and Many More

[cnxvideo id=”509736″ placement=”ros”]Stocks have pulled back off their highs from the end of 2016 and that Dow Jones Industrial Average…

Lee Jackson | Jan 10, 2017 at 8:35 AM EST

Jefferies Has 5 Top Biotech Stocks to Buy for 2017

Needless to say, the past two years have been rough on biotech. The question for investors is which of the…

Lee Jackson | Jan 6, 2017 at 8:35 AM EST

These 5 Biotech Stocks Could Be Big Takeover Targets in 2017

A new Jefferies research report makes the case that five top biotech companies may be right in the cross-hairs of…

Lee Jackson | Aug 31, 2016 at 8:20 AM EDT

3 Biotech Stocks Could Be the Next Big Takeover Targets

In a new research report, Baird notes two biotech companies in its research coverage universe that may be considered speculative…

Lee Jackson | Jun 13, 2016 at 8:15 AM EDT

Analysts Very Positive on 3 Top Stocks Following Jefferies Healthcare Conference

The Jefferies Healthcare Conference wrapped up in New York City last week, and the mood was reported as generally positive,…

Chris Lange | Apr 6, 2016 at 10:05 AM EDT

5 Biotechs With the Most Upside This Earnings Cycle

Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help…

Chris Lange | Mar 29, 2016 at 9:35 AM EDT

8 Major Biopharma Events Coming Later in 2016 and in 2017

FDA rulings can make or break some companies. 24/7 Wall St. has collected eight key FDA decisions coming up in…

1 … 3 4 5 6 7 … 10

Incyte : INCY

All Incyte Articles

Analysts See 10 Companies Beating Expectations This Earnings Season

Jefferies Thinks 3 Red-Hot Biotech Stocks Can Beat Q1 Estimates

The 5 Best Performing S&P 500 Stocks for Q1

Top-Performing S&P 500 Stocks Already Showing Gains of 30% to 50% in 2017

What a Combined Gilead and Incyte Would Look Like

Top 5 Earnings to Look For on Tuesday

Why This Collaboration Is So Important for Calithera

Why Credit Suisse Sees Incyte Rising Over 15%

Top Analyst Upgrades and Downgrades: Ally, IBM, MetLife, Qualcomm, Verizon, Williams, Incyte and Many More

Jefferies Has 5 Top Biotech Stocks to Buy for 2017

These 5 Biotech Stocks Could Be Big Takeover Targets in 2017

3 Biotech Stocks Could Be the Next Big Takeover Targets

Analysts Very Positive on 3 Top Stocks Following Jefferies Healthcare Conference

5 Biotechs With the Most Upside This Earnings Cycle

8 Major Biopharma Events Coming Later in 2016 and in 2017

COPX vs. CPER: Do Copper Miners or Copper Futures Best Play the Electrification Squeeze?

A Widow Turned Down the Survivor Check at 60 to Protect a Bigger One Later. The Wait Cost Her $50,000.

He Kept His Spouse’s Employer Plan Past 65. Medicare Called It a Gap — and Charged Him for Life.

A Widow Turned Down the Survivor Check at 60 to Protect a Bigger One Later. The Wait Cost Her $50,000.

He Kept His Spouse's Employer Plan Past 65. Medicare Called It a Gap — and Charged Him for Life.

COPX vs. CPER: Do Copper Miners or Copper Futures Best Play the Electrification Squeeze?

A Widow Turned Down the Survivor Check at 60 to Protect a Bigger One Later. The Wait Cost Her $50,000.

Incyte : INCY

All Incyte Articles

Analysts See 10 Companies Beating Expectations This Earnings Season

Jefferies Thinks 3 Red-Hot Biotech Stocks Can Beat Q1 Estimates

The 5 Best Performing S&P 500 Stocks for Q1

Top-Performing S&P 500 Stocks Already Showing Gains of 30% to 50% in 2017

What a Combined Gilead and Incyte Would Look Like

Top 5 Earnings to Look For on Tuesday

Why This Collaboration Is So Important for Calithera

Why Credit Suisse Sees Incyte Rising Over 15%

Top Analyst Upgrades and Downgrades: Ally, IBM, MetLife, Qualcomm, Verizon, Williams, Incyte and Many More

Jefferies Has 5 Top Biotech Stocks to Buy for 2017

These 5 Biotech Stocks Could Be Big Takeover Targets in 2017

3 Biotech Stocks Could Be the Next Big Takeover Targets

Analysts Very Positive on 3 Top Stocks Following Jefferies Healthcare Conference

5 Biotechs With the Most Upside This Earnings Cycle

8 Major Biopharma Events Coming Later in 2016 and in 2017

COPX vs. CPER: Do Copper Miners or Copper Futures Best Play the Electrification Squeeze?

A Widow Turned Down the Survivor Check at 60 to Protect a Bigger One Later. The Wait Cost Her $50,000.

He Kept His Spouse’s Employer Plan Past 65. Medicare Called It a Gap — and Charged Him for Life.

Featured Reads

A Widow Turned Down the Survivor Check at 60 to Protect a Bigger One Later. The Wait Cost Her $50,000.

He Kept His Spouse's Employer Plan Past 65. Medicare Called It a Gap — and Charged Him for Life.